OncoMatch/Clinical Trials/NCT06381817
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Is NCT06381817 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Haplo-cord HCT and Haplo-HCT for acute t cell lymphoblastic leukemia.
Treatment: Haplo-cord HCT · Haplo-HCT — The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are: Dose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL. Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: autologous hematopoietic cell transplantation
Cannot have received: allogeneic hematopoietic cell transplantation
Cannot have received: car-t cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06381817 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation, car-t cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages